Sleep Quality and Architecture
Studies examine sleep efficiency, awakenings, and sleep stages. Some reported changes in selected measures; others found limited or uncertain benefit.
Sleep & Peptide Education
DSIP (Emideltide)
Explore emerging sleep research and personalized guidance for your sleep-health concerns.
Book Your AppointmentWhat Is DSIP?
Delta Sleep-Inducing Peptide (DSIP), also called emideltide, is a nine-amino-acid peptide investigated for its relationship to sleep and neuroendocrine signaling. Its precise role in humans remains unresolved.
An emerging research topic: DSIP is not an FDA-approved sleep medication. Small, largely older human studies have produced mixed findings, leaving clinical effectiveness and safety uncertain.
Why Researchers Study DSIP
Early investigations explored changes in sleep onset, duration, and continuity. These findings sparked interest, but have not established a reliable treatment effect.
Circadian and Sleep-Wake Processes
Research explores possible relationships with daily rhythms and sleep initiation. DSIP has not been shown to reliably reset a person’s sleep cycle.
Stress and Neuroendocrine Signaling
Experimental work examines connections between nervous-system activity, hormones, and stress responses. Therapeutic conclusions remain premature.
Other Historical Research
DSIP has also been explored in narcolepsy and opioid withdrawal. This research does not establish treatment effectiveness for either condition.
Putting Sleep Research in Perspective
Better sleep involves more than a single signal or compound. Research on DSIP can be discussed alongside a broader look at your symptoms and health.
What Was Measured?
A change in one sleep measurement does not necessarily mean meaningful improvement in daily functioning or well-being.
How Strong Is the Study?
Small samples, older methods, and inconsistent findings limit confidence. Modern, larger controlled trials are needed.
What Is Still Unknown?
Optimal dosing, route, duration, interactions, and long-term safety have not been established.
Start With Your Sleep Concerns
Persistent insomnia or daytime sleepiness deserves a clinical assessment. Your visit can explore what is disrupting sleep and which established options fit your needs.
Review the Full Picture
Discuss sleep schedule, snoring, medications, stress, mood, and relevant medical or hormonal concerns.
Find a Practical Next Step
Your provider may recommend testing, sleep-specialist evaluation, or established care rather than an investigational peptide.
Safety: What We Know and What We Do Not
Limited human evidence means the full adverse-effect profile is unknown. A short list of reported symptoms should not be mistaken for a complete safety assessment.
Immune and Product Concerns
FDA has identified potential immune-reaction risks and concerns involving peptide impurities and ingredient characterization, with insufficient safety information for proposed routes.
Interactions and Individual Health
Effects with sedatives and other medications are not adequately studied. Pregnancy, breastfeeding, and significant neurologic or psychiatric conditions require particular caution and professional guidance.
Injection routes add risks such as irritation, contamination, and infection. Research descriptions are not administration instructions; do not self-experiment with unverified products.
Questions to Bring to Your Consultation
A useful discussion connects the research to your actual sleep experience.
Your Sleep Pattern
When did the problem begin? Is the difficulty falling asleep, staying asleep, or feeling rested?
Your Health and Medications
What conditions, prescriptions, supplements, or schedule changes might contribute?
Your Care Options
What testing or established treatments might help, and how will progress be assessed?
Research Review & Pharmacy Standards
Emideltide-related substances have undergone FDA compounding advisory review. That process is separate from drug approval and does not itself establish access to a product.
Understand the Status
A substance registration, nomination, or committee discussion does not mean FDA has approved DSIP or added it to a final compounding list.
Avoid Assumptions About Availability
Any potential offering must meet current federal and state requirements. This page does not promise a prescription, supply, or future availability date.
Compounded medicines are not FDA-approved. A licensed pharmacy or independent quality testing does not replace evidence of clinical safety or establish permission to compound a particular substance.
Frequently Asked Questions
Are DSIP and emideltide the same?
Yes. Emideltide is another name for delta sleep-inducing peptide, a nine-amino-acid peptide.
Is DSIP FDA-approved?
No. FDA compounding review and substance registration should not be confused with approval of a medicine.
Can DSIP treat insomnia?
Small historical studies investigated insomnia, but findings are mixed and insufficient to establish DSIP as a standard treatment.
Does it improve deep sleep?
Available evidence does not establish a reliable increase in deep sleep or a predictable change in sleep stages.
Is it like a conventional sleeping pill?
DSIP’s mechanisms and effects remain incompletely understood. It should not be assumed to act like, or be safer than, established sleep medicines.
Can it be combined with sleep medications or other peptides?
Interactions and combination safety are not established. Bring a complete medication and supplement list to your clinician; do not add an investigational product on your own.
What can Alpha Hormones help me with?
Our team can review sleep concerns, medical history, and research questions, then discuss appropriate evaluation and available care options. A consultation does not guarantee DSIP access.
Personalized Guidance for Better Sleep
Our Pasadena team takes time to understand your concerns and explain your options.
Bring your questions about DSIP, sleep research, and your health goals. Together, we can identify an appropriate next step.
